Diabetic Macular Edema / Diabetic Retinopathy | Current Treatment | Detailed, Expanded Analysis (US)

Publish date: May 2016

Login to access report

Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market, as a result of multiple intravitreal pharmacotherapy product approvals across different drug classes in recent years. Although laser photocoagulation has long been the standard of care for patients with the most advanced stages of DR, recent clinical trial results suggest that intravitreal pharmacotherapy injections may be effective treatment for this broader patient population as well. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment overview provides a synopsis of current treatment goals, key therapies, and medical practice in the United States and EU5 markets for DR and DME. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment | US detailed, expanded analysis offers a snapshot of how U.S. ophthalmologists are currently treating their DR and DME patients, with a particular focus on use of intravitreal vascular endothelial growth factor (VEGF) inhibitors and intravitreal corticosteroid implants, as well as insight into the factors driving such prescribing habits.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Diabetic Retinopathy's High Disease Burden
      • Treatment Practices
        • VEGF Inhibitors Dominate the Early-Line Treatment Algorithm for Diabetic Macular Edema
        • Time to Treatment Start
        • Treatment Rates
        • Patient Share by Product
        • Treatment Duration by Product
        • Use of Nonpharmacological Approaches
        • Line of Therapy Analysis
        • Combination/Regimen/Comedication Analysis
      • Persistency and Compliance
        • IVT Agents Are Associated with High Compliance and Persistence for Diabetic Macular Edema
      • Sequencing of Treatment
        • Switching Is Common Within the Anti-VEGF Drug Class
      • Recent/Anticipated Changes in Brand Usage/Treatment Approach
        • Anti-VEGF Patient Shares Are Expected to Remain Stable One Year from Now for Diabetic Macular Edema
    • Physician Insight on Medical Practice
      • Key Findings
      • Drivers of Treatment Selection
        • Cost and Efficacy Drive Prescribing Decisions in Diabetic Macular Edema
        • Factors Influencing Treatment and Disease Management
        • Major Drivers of Brand Usage/Treatment
        • Major Obstacles for Brand Usage/Treatment
        • Rationale for Treatment Switching by Therapy/Approach
        • Rationale for Therapy Discontinuation
        • Rationale for Treatment Deferral by Therapy/Approach
      • Face-to-Face Product Detailing Effectiveness
        • Diabetic Macular Edema-Specific Visits by Sales Representatives Are Infrequent but Well Received
        • Sales Representative Frequency and Reach
        • Sales Representative Satisfaction
        • Message Recall
    • Methodology
      • Primary Market Research Methodology
      • Claims Data Methodology
      • Limitations of Comparative Analyses Between Data Sources
    • Appendix
      • Primary Market Research
      • Claims Data

Author(s): Emma McFadden, PhD

Emma McFadden, is a  Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and ; Prior to joining Decision Resources Group, Emma earned a in neuroscience and a in biochemistry from Trinity College Dublin.